225 related articles for article (PubMed ID: 1785379)
21. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
Takata R; Obara W; Fujioka T
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S41-5. PubMed ID: 20094952
[TBL] [Abstract][Full Text] [Related]
22. Systemic chemotherapy for muscle invasive bladder cancer.
Ondrus D; Hornák M; Bárdos A; Ondrus B
Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
[TBL] [Abstract][Full Text] [Related]
23. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
Shimabukuro T; Nakamura K; Uchiyama K; Tei Y; Aoki A; Naito K
Hinyokika Kiyo; 2006 Feb; 52(2):99-105. PubMed ID: 16541762
[TBL] [Abstract][Full Text] [Related]
25. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
Keating JP; Zincke H; Hahn RG; Morgan WR
Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
[No Abstract] [Full Text] [Related]
26. [Study of the combined M-VAC therapy in invasive bladder cancer].
Asano K; Masuda F; Suzuki H; Takamizawa S; Kaneko R
Hinyokika Kiyo; 1991 Dec; 37(12):1645-50. PubMed ID: 1785388
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
28. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
Yamashita S; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Yushita Y; Sakuragi T
Hinyokika Kiyo; 1992 May; 38(5):519-24. PubMed ID: 1609658
[TBL] [Abstract][Full Text] [Related]
29. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle.
Arias F; Dueñas M; Martínez E; Domínguez MA; Illarramendi JJ; Villafranca E; Tejedor M; Molina F; Meiriño R; Valerdi JJ
Cancer; 1997 Jul; 80(1):115-20. PubMed ID: 9210716
[TBL] [Abstract][Full Text] [Related]
30. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
32. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
33. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
[TBL] [Abstract][Full Text] [Related]
35. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
36. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
Matveev BP; Figurin KM
Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
[TBL] [Abstract][Full Text] [Related]
37. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
Campo B; Torelli T; Leidi GL; Corrada P; Bacchioni AM; Ordesi G; Zanitzer L
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):237-42. PubMed ID: 2142807
[TBL] [Abstract][Full Text] [Related]
38. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
39. [Place of chemotherapy in the treatment of invasive bladder tumors].
Pariente JL; Theodore C; Davin JL; Rischmann P; Chopin D
Prog Urol; 1999 Apr; 9(2):219-24. PubMed ID: 10370944
[TBL] [Abstract][Full Text] [Related]
40. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
